Stock abbreviation: Zhejiang Hisun Pharmaceutical Co.Ltd(600267) Stock Code: Zhejiang Hisun Pharmaceutical Co.Ltd(600267) Announcement No.: Lin 202261 bond abbreviation: Haizheng fixed transfer bond Code: 110813
Zhejiang Hisun Pharmaceutical Co.Ltd(600267)
Announcement on adjusting the total cash dividends of profit distribution in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Total cash dividend to be distributed: adjusted from 16634263842 yuan (tax included) to 16632505442 yuan (tax included).
Reasons for this adjustment: Zhejiang Hisun Pharmaceutical Co.Ltd(600267) (hereinafter referred to as “the company”) is reserved to grant restricted stock incentive plan in 2021, with 2626000 new shares. On April 12, 2022, the registration procedures of new shares have been completed in Shanghai Branch of China Securities Depository and Clearing Corporation Limited, and the total share capital of the company has been changed to 1198657562 shares. Up to now, the company has repurchased 10621459 shares in total. The company adjusted the total distribution amount of the profit distribution plan in 2021 according to the principle of unchanged distribution amount per share.
1、 Profit distribution plan for 2021 approved by the general meeting of shareholders
On April 19, 2022, the 2021 annual general meeting of shareholders of the company deliberated and approved the 2021 annual profit distribution plan. The company will distribute cash of 1.4 yuan (including tax) to all shareholders for every 10 shares based on the total share capital registered on the date of equity distribution and equity registration minus the number of shares in the company’s special securities account. In 2021, there will be no share distribution and capital reserve will not be converted into share capital. According to the total share capital of the company at the time of disclosure of the profit distribution plan minus 7869859 shares repurchased in the special securities account for repurchase at that time, the cash dividend to be distributed is 16634263842 yuan (including tax). If before the date of equity distribution and equity registration, the total share capital of the company changes due to the conversion of convertible bonds into shares, repurchase of shares, repurchase cancellation of equity incentive grant shares and reserved part of share grant registration, the company plans to maintain the distribution amount per share unchanged and adjust the total distribution accordingly. For details, please refer to Zhejiang Hisun Pharmaceutical Co.Ltd(600267) announcement on profit distribution plan for 2021 (public notice)
Report No.: Lin 202222), which has been published in China Securities Journal, Shanghai Securities News, securities times and the website of Shanghai Stock Exchange (www.sse. Com. CN) on March 29, 2022 Come on.
2、 Relevant changes since the disclosure of profit distribution plan
(1) Reserved grant registration of restricted stock incentive plan in 2021
On December 2022, the company issued the certificate of change of stock capital of the company into a limited liability company of 26862 shares, which has been registered as a limited liability company in China.
(2) Share repurchase of the company
On March 29, 2022, when the company’s 2021 profit distribution plan was disclosed, the company had repurchased 7869859 shares. In April 2022, the company newly repurchased 2751600 shares. Up to now, the number of shares in the special securities account for repurchase held by the company is 10621459. According to Article 23 of the guidelines for self discipline supervision of listed companies on Shanghai Stock Exchange No. 7 – share repurchase, “listed companies that repurchase shares in the special account do not enjoy the rights of voting at the general meeting of shareholders, profit distribution, conversion of reserve funds into share capital, subscription of new shares and convertible corporate bonds, and shall not pledge or lend.” Accordingly, 10621459 repurchased shares registered under the name of the special securities account for repurchase will not participate in this distribution, and the total number of shares actually participating in this distribution is 1188036103.
As of the disclosure date of this announcement, “Haizheng fixed transfer” (bond Code: 110813) has not been converted into shares. In addition, from May 20, 2022 to the equity distribution registration date (May 26, 2022), the “Haizheng fixed transfer” will stop the conversion of shares. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on May 17, 2022 And the notice of Zhejiang Hisun Pharmaceutical Co.Ltd(600267) on stopping the conversion of shares and adjusting the conversion price of “Haizheng dingzhuan” during the implementation of annual equity distribution in 2021 (Announcement No.: Lin 202259) disclosed on the designated information disclosure media of the company. Therefore, up to the equity distribution registration date (May 26, 2022), the total share capital of the company will not change due to the conversion of convertible bonds into shares.
3、 Notes on adjusting the total cash dividends of profit distribution in 2021
To sum up, in view of the changes in the total share capital of the company and the actual number of dividend shares caused by the repurchase of shares, that is, the total share capital of the company is 1198657562 shares. After deducting 10621459 repurchased shares not participating in profit distribution, the actual number of shares participating in profit distribution is 1188036103 shares. The company kept the distribution proportion per share unchanged and distributed cash of 1.4 yuan (including tax) to all shareholders for every 10 shares. Based on this calculation, the total amount of cash dividends distributed was adjusted to 16632505442 yuan (including tax).
It is hereby announced.
Zhejiang Hisun Pharmaceutical Co.Ltd(600267) board of directors may 21, 2002
